CG
LABU icon

Cutler Group’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Cutler Group’s Portfolio LABU Stock Details LABU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$8K Sell
66
-6,995
-99% -$913K ﹤0.01% 1377
2023
Q4 		$861K Buy
+7,061
New +$540K 0.08% 284
2023
Q3 		– Sell
-332
Closed -$34.1K – 4084
2023
Q2 		$39K Sell
332
-453
-58% -$56.5K 0.01% 1444
2023
Q1 		$77K Sell
785
-3,320
-81% -$450K 0.01% 1119
2022
Q4 		$580K Buy
4,105
+2,570
+167% +$358K 0.05% 396
2022
Q3 		$215K Sell
1,535
-773
-33% -$142K 0.01% 922
2022
Q2 		$311K Sell
2,308
-1,942
-46% -$331K 0.02% 745
2022
Q1 		$1.33M Sell
4,250
-3,665
-46% -$1.38M 0.07% 311
2021
Q4 		$5.7M Buy
7,915
+5,620
+245% +$5.38M 0.24% 79
2021
Q3 		$2.54M Buy
+2,295
New +$2.82M 0.11% 192
2021
Q2 		– Sell
-144
Closed -$200K – 6049
2021
Q1 		$227K Buy
144
+26
+22% +$60.9K 0.01% 1184
2020
Q4 		$236K Buy
+118
New +$188K 0.01% 993
2020
Q2 		– Sell
-489
Closed -$424K – 4645
2020
Q1 		$220K Sell
489
-458
-48% -$417K 0.01% 898
2019
Q4 		$1.09M Sell
947
-908
-49% -$815K 0.07% 247
2019
Q3 		$1.15M Buy
+1,855
New +$1.54M 0.1% 170
2019
Q1 		– Sell
-10
Closed -$10.4K – 4419
2018
Q4 		$6K Buy
+10
New +$10.5K ﹤0.01% 2837
2018
Q2 		– Sell
-15
Closed -$26.4K – 4562
2018
Q1 		$23K Sell
15
-15
-50% -$27.9K ﹤0.01% 2183
2017
Q4 		$46K Sell
30
-434
-94% -$664K ﹤0.01% 1931
2017
Q3 		$792K Buy
464
+398
+603% +$552K 0.03% 435
2017
Q2 		$83K Sell
66
-55
-45% -$55.5K ﹤0.01% 2017
2017
Q1 		$115K Sell
121
-1,421
-92% -$1.27M ﹤0.01% 1604
2016
Q4 		$965K Buy
1,542
+1,500
+3,571% +$1.13M 0.03% 427
2016
Q3 		$40K Sell
42
-100
-70% -$82.5K ﹤0.01% 2679
2016
Q2 		$80K Buy
142
+80
+129% +$50.1K ﹤0.01% 1896
2016
Q1 		$33K Buy
62
+56
+933% +$35.4K ﹤0.01% 2752
2015
Q4 		$10K Buy
+6
New +$9.72K ﹤0.01% 4137

Other funds holding LABU

Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
TI
Tidal Investments Milwaukee, Wisconsin $47.4B AUM 59.58% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

Cutler Group's LABU Position: Q1 2024 in Review

Cutler Group reduced its Direxion Daily S&P Biotech Bull 3X ETF (LABU) stake by 99% in Q1 2024, selling an estimated $913K and leaving 66 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #1377.

Cutler Group first reported a position in LABU in Q4 2015 and has held it in 26 quarters since. The position peaked at $5.7M in Q4 2021. 33 funds tracked by Wall St. Rank hold LABU as of Q1 2024.

  • Cutler Group held 66 shares of Direxion Daily S&P Biotech Bull 3X ETF worth $8K as of Q1 2024.
  • Cutler Group sold 6,995 Direxion Daily S&P Biotech Bull 3X ETF shares in Q1 2024, an estimated $913K.
  • Direxion Daily S&P Biotech Bull 3X ETF made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1377 holding.
  • Cutler Group first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q4 2015 and has held it in 26 quarters since.
  • Cutler Group's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $5.7M in Q4 2021.
  • 33 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.